Lunit Highlights AI-Powered IHC and Tumor Microenvironment Research at ASCO 2026
Summary
Lunit will present five studies at ASCO 2026 showcasing its AI biomarker platforms for integrated HER2/IHC quantification and spatial tumor microenvironment analysis. The research spans multiple cancer types and includes a Rapid Oral presentation on a HER2-positive biliary tract cancer trial that used AI whole-slide analysis to link HER2 IHC proportions with response rates and progression-free survival. Other studies use AI spatial profiling to reveal immune-cold phenotypes in HER2-overexpressing NSCLC, identify axitinib responders in adenoid cystic carcinoma via endothelial and TIL densities, and find TLS-associated benefit in MSS metastatic colorectal cancer. Lunit is promoting its Lunit SCOPE and clinically validated imaging solutions and will exhibit its platforms and collaborations at the meeting.
Classifications
AskAI Classifications
LabelsLinked Companies
